Jax DiEugenio

VERITAC-2 PRO Data Support Potential of Vepdegestrant in ESR1-Mutated ER+ Advanced Breast Cancer

October 28th 2025

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Y-90 Resin Microspheres Show Favorable Safety, Reinforcing Role in HCC

October 24th 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

FDA Approves Revumenib for Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia

October 24th 2025

The FDA approved revumenib for adult and pediatric patients at least 1 year of age with relapsed or refractory AML with a susceptible NPM1 mutation.

Dr Sweis on the Potential for XmAb819 to Fill Treatment Gaps in Refractory RCC

October 24th 2025

Randy F. Sweis, MD, discusses shares how XmAb819 may address the need for effective therapies after progression on standard regimens in RCC.

Dr Peters on Obrixtamig Plus Atezolizumab/Chemo in First-Line ES-SCLC

October 24th 2025

Solange Peters, MD, PhD, discusses findings for obrixtamig plus atezolizumab/chemotherapy in first-line extensive-stage small cell lung cancer.

Dr Xie on the Rationale for Investigating HS-20093 in Relapsed/Refractory Sarcomas

October 23rd 2025

Lu Xie, MD, discusses the scientific rationale and clinical development strategy for HS-20093 in the phase 2 ARTEMIS-002 trial.

FDA Approves Belantamab Mafodotin Plus Bortezomib and Dexamethasone for R/R Multiple Myeloma

October 23rd 2025

Dr Wang on a Retrospective Study of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 23rd 2025

Pule Wang, MD, discusses the design of a retrospective study of CNS bridging radiation therapy prior to CAR T in B-cell lymphomas.

FDA Approval of Y-90 Resin Microspheres Marks a New Chapter for Radioembolization in Unresectable HCC

October 23rd 2025

Armeen Mahvash, MD, discusses how the FDA approval of SIR-Spheres Y-90 resin microspheres highlights the growing role of radioembolization in unresectable HCC.

WES-Aneuploidy Scores May Be Prognostic for Immunotherapy in dMMR Endometrial Cancer

October 23rd 2025

WES-aneuploidy scores may identify patients with dMMR endometrial cancer who do not benefit from the addition of immunotherapy to chemotherapy.

Vopimetostat Demonstrates Early Evidence of Efficacy in MTAP-Deleted Solid Tumors

October 23rd 2025

Vopimetostat elicited responses and was considered tolerable in patients with MTAP-deleted solid tumors, including pancreatic and lung cancers.

Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC

October 23rd 2025

The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.

FDA Grants Priority Review to Perioperative Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible MIBC

October 23rd 2025

The FDA granted priority review to enfortumab vedotin plus pembrolizumab as perioperative therapy for cisplatin-ineligible muscle-invasive bladder cancer.

Adjuvant Cemiplimab Approval Redefines Management of High-Risk CSCC

October 23rd 2025

Adjuvant cemiplimab significantly cut recurrence risk and improved disease-free survival in high-risk CSCC, establishing a new standard of care.

Dr Tagawa on the Rationale for Evaluating Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 22nd 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Dr Hassel on the Rationale for Combining IO102-IO103 with Pembrolizumab in Treatment-Naive Advanced Melanoma

October 22nd 2025

Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC

October 22nd 2025

Atezolizumab plus bevacizumab displayed preliminary signs of a TTFS benefit vs TACE in intermediate-stage HCC.

Dr Saad on Long-Term Data With Radium-223 Plus Enzalutamide in mCRPC With Bone-Predominant Disease

October 22nd 2025

DSMB Recommends Continuation of Phase 3 Study of Bria-IMT in Metastatic Breast Cancer

October 22nd 2025

A data safety monitoring board recommended the continuation of a study of Bria-IMT plus immune checkpoint inhibition in metastatic breast cancer.

Dr Dreyling on the Recommended Use of Acalabrutinib Plus BR in Pretreated MCL

October 22nd 2025

Martin Dreyling, MD, provides recommendations for use of acalabrutinib plus BR in pretreated MCL based on updated data from the phase 3 ECHO trial.